1 Department of Pathology, Virginia Commonwealth University, Richmond, VA; greg.miller@vcuhealth.org.
2 Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA;
3 Former Chair of the IFCC Committee on Reference Intervals and Decision Limits (2006-2010) and collaborator in the CLSI document EP 28-A3, and Clinical Laboratory Service, San Raffaele Hospital, Milano, Italy;
4 Vice President and Director, Department of Science and Technology, Laboratory Corporation of America, Holdings, Elon, NC;
5 Principal Consultant, Neil Greenberg Consulting, LLC, Rochester, NY, and Convenor, ISO/TC212 Working Group 2;
6 Associate Vice President and Director, Clinical Science Assessment, Department of Science and Technology, Laboratory Corporation of America Holdings, Elon, NC;
7 Chemical Pathologist, SydPath, Department of Chemical Pathology, St. Vincent's Hospital, Sydney, and Associate Professor, Faculty of Medicine, University of New South Wales, Sydney, Australia;
8 Professor of Medicine, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY;
9 Professor of Medicine, Department of Medicine, Queen's University, Belfast, Wellcome Research Laboratories Mulhouse Building, Royal Victoria Hospital, Belfast, UK.